Clinical trial
Glivec Phase II Pediatric Study
NCT00180830 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Terminated
Key facts
| NCT number | NCT00180830 |
|---|---|
| Title | Glivec Phase II Pediatric Study |
| Official title | Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Glivec, Gleevec |
| Enrollment | 36 |
| Start date | Dec 1, 2003 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | France, Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: